INTRODUCTION {#sec1-1}
============

Cisplatin, a platinum-based therapeutic, is a chemotherapeutic agent that is widely used for the treatment of many human solid tumors. However, serious adverse effects, for example its neuro-toxic and nephro-toxic effects, limit its clinical use([@ref1][@ref2][@ref3]). Cisplatin therapeutic effects, as well as its adverse effects, are dose-dependent. The mechanism underlying cisplatin-induced unwanted side effects is complex and has not been fully understood. Mitochondrial oxidative stress, DNA damage, inflammation, and apoptosis of normal tissues are some of the side effects of cisplatin in tissues([@ref3][@ref4][@ref5][@ref6]).

*Cornus mas* L. (Cornelian cherry, *C. mas*) is a medicinal plant that belongs to the Cornacea species([@ref7][@ref8]). The plant is found in parts of Asia, including the north-west forests of Iran (Arasbaran, East Azerbaijan) and also central and southern Europe([@ref8]). The fruit of the Cornelian cherries are typically olive-shaped, 10-23 mm in length, single-seeded red fruits with a sweet-sour taste. The fruits are rich in sugar, organic acids, oxalic acid, tannins, anthocyanins, phenols, flavonoids, and other antioxidants. Fresh Cornelian cherry fruits contain B1, B2, C, and E vitamins, as well as folic acid([@ref7][@ref8][@ref9]). The fruits have been used for the treatment of many disorders in traditional and conventional medicine([@ref8][@ref9][@ref10]).

The present study was performed to investigate the effects of *C. mas* as a natural antioxidant([@ref11]) on the blood lipid profile, antioxidant enzymes, and hematologic parameters of male Wistar rats, as well as to analyze the probable effects of *C. mas* fruit hydro-methanolic extract on the parameters after cisplatin administration.

MATERIALS AND METHODS {#sec1-2}
=====================

 {#sec2-1}

### Plant ingredients and extraction {#sec3-1}

The *C. mas* fruits were purchased from the suburbs of Kaleibar (East Azarbaijan, Iran). The fruits were washed and their seeds were removed manually. The fruit parts were air-dried and then turned into a coarse powder. Then, 500 g of the fine powder was extracted by methanol (Merck, Germany) and water mixture in the ratio of 7:3 at 25 ± 2 °C. The mixture was then filtered (0.45 μ pore size) and the solvents were completely removed by a rotary vacuum evaporator (Hidolf, Germany) at 40 °C. Finally, the *C. mas* methanolic extract (CME) was frozen and stored at -80 °C until it was ready to use([@ref8]).

### Analyses of *Cornus mas* hydro-methanolic extract {#sec3-2}

The total phenolic contents of the CME were assayed using Folin-Ciocalteu reagent and gallic acid standard curve, and expressed as mg of gallic acid equivalents (GAE) per gram of the extract([@ref12]). The total flavonoids of the CME were determined using the spectrophotometric method as described by Vador, *et al*.([@ref13][@ref14]). The antioxidant properties of the CME were assayed by the DPPH assay method([@ref13]) and the 50% reduction capacity (RC~50~) was expressed as mg/mL.

### Animals {#sec3-3}

Forty male Wistar rats, weighing 200 ± 20 g, were obtained from Pasteur Institute (Karaj, Iran). The animals were housed in a temperature-controlled room (22 ± 2 °C) with 12/12 h of light/dark cycles with a standard rat pellet diet and clean drinking water *ad libitum*. All the animal procedures were approved by the Animal Research Ethics Committee of Tabriz University of Medical Sciences (ethical approval code: 5-4-1171) and were carried out in accordance with the related guidelines.

### Experimental design {#sec3-4}

The animals were randomly divided into five groups (n = 8) as follows:([@ref1]) the normal control group; orally received distilled water (DW) daily by gavage needle for 16 days and an IP injection of sterile DW water on day 11;([@ref2]) the CME group, orally received 700 mg/kg bw CME daily for 16 days and an IP injection of DW on day 11;([@ref3]) the CME 300 + Cis group, orally received 300 mg/kg bw CME daily for 16 days and an IP injection of 5 mg/kg bw cisplatin on day 11;([@ref4]) the CME 700 + Cis group, orally received 700 mg/kg bw CME daily for 16 days and an IP injection of 5 mg/kg bw cisplatin on day 11;([@ref5]) the Cis group, orally received DW daily for 16 days and an IP injection of 5 mg/kg cisplatin on day 11([@ref15][@ref16][@ref17]).

At the end of the experimental period, the blood samples were taken from each animal by cardiac puncture. The samples were transferred into tubes containing ethylenediaminetetraacetic acid (EDTA) as the hematology anticoagulant and clot tubes for biochemical analyses.

The clot tubes were centrifuged at 2000 g at 4 °C for 10 min. The blood serum samples were separated and stored in a freezer at -80 °C until use.

### Biochemical analyses {#sec3-5}

The blood triglyceride, cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) were determined by the enzymatic methods using commercial kits (Pars Azmun, Karaj, Iran). The total antioxidant capacity (TAC), superoxide dismutase (SOD), and glutathione peroxidase (GPx) were assayed by commercial kits (Randox, Italy). Catalase activities were determined by a Cayman kit (USA). Malondialdehyde (MDA) contents were analyzed by a barbituric acid method. After calibrating and validating these tests using several calibrators, the automated Abbott biochemistry analyser (Alcyon 300, USA) was used for performing the tests.

### Hematological analyses {#sec3-6}

The hematology indices including hemoglobin (Hb), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV), red blood cells (RBC), packed cell volume (PCV), red cell distribution width (RDW), hemoglobin distribution width (HDW), platelet, mean platelet volume (MPV), plateletcrit (PCT), platelet distribution width (PDW), basophil, eosinophil, lymphocyte, leucocyte, monocyte, neutrophil, and white blood cells (WBC) were assayed by the Technicon-H1 (Bayer, Germany) hematology analyzer([@ref8]). The results of the analyzer were checked by microscopic analyses of the stained blood smears (May-Grünwald and Giemsa- Romanowski).

### Statistical analyses {#sec3-7}

Statistical analyses were performed using SPSS (V. 20) for Windows (SPSS Inc., Chicago, IL, USA). One-way analysis of variance (ANOVA) followed by Tukey posthoc multiple comparison tests was used to compare the parameters between the groups. The data were expressed as mean ± standard deviation (SD). P-values less than 0.05 and 0.01 were considered statistically significant.

RESULTS {#sec1-3}
=======

 {#sec2-2}

### Antioxidant indices of *Cornus mas* hydro-methanolic extract {#sec3-8}

Composition of the CME in terms of poly-phenolic and flavonoid compounds and antioxidant properties are represented in [Table 1](#T1){ref-type="table"}.

###### 

Composition of *Cornus mas* hydro-methanolic fruit extract (CME) (n = 3).
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### Effects on lipid profile and antioxidant enzymes {#sec3-9}

[Table 2](#T2){ref-type="table"} displays the status of all biochemical parameters measured in this research. The effects of the cisplatin on blood serum triglyceride, cholesterol, HDL, and LDL levels were not statistically significant (*P* \> 0.05). However, the lowering effect of CME on blood cholesterol and HDL in all CME-treated groups was significant (*P* \< 0.01). The serum GPx (*P* \< 0.05) and catalase (*P* \< 0.01) levels were significantly decreased and the MDA level (*P* \< 0.05) was significantly increased in the Cis group when compared with the control. The administration of CME, together with Cis, reversed the GPx, catalase, and MDA results to the values that were not significantly different from the control levels ([Table 2](#T2){ref-type="table"}).

###### 

Blood serum lipid profile and antioxidant parameters of the *Cornus mas* hydro-methanolic fruit extract and cisplatin treated rats (n = 8).
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### Effects on red blood cell parameters {#sec3-10}

[Table 3](#T3){ref-type="table"} displays the status of red blood cell parameters explored. The Hb of the rats in the Cis group was significantly higher than that of the control group (*P* \< 0.01). However, in the co-treated groups, the Hb levels were not significant (*P* \> 0.05). On the other hand, in the CME group, the RBC counts were significantly lower (*P* \< 0.01) and the RDW, (*P* \< 0.01) and HDW, (*P* \< 0.05) levels were significantly higher than those of the control group ([Table 3](#T3){ref-type="table"}).

###### 

Red blood cell parameters of the *Cornus mas* fruit hydro-methanolic extract and cisplatin treated rats (n = 8).
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### Effects on platelet parameters {#sec3-11}

[Table 4](#T4){ref-type="table"} displays the values of platelet parameters measured in this study. Significant increase of platelet in the CME 300 + Cis group (*P* \< 0.01), a decrease of MPV in the Cis group (*P* \< 0.05) and an increase of PCT in the CME and CME 300 + Cis groups (*P* \< 0.01) in comparison with the control group were observed.

###### 

Platelet parameters of the *Cornus mas* fruit hydro-methanolic extract and cisplatin treated rats (n = 8).
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### Effects on white blood cell parameters {#sec3-12}

[Table 4](#T4){ref-type="table"} displays the values of WBC parameters assayed in this study. In the cisplatin-treated group, WBCs (*P* \< 0.05), neutrophils (*P* \< 0.01), monocytes (*P* \< 0.01), basophils (count, *P* \< 0.05), and large unstained cells (*P* \< 0.01) were significantly increased, while lymphocytes (percent, *P* \< 0.01) were significantly decreased when compared with the control group. The CME co-administration showed no significant reduction on the WBC levels when compared to the Cis group (*P* \> 0.05). However, the neutrophil, monocytes, basophils (count), large unstained cells, and lymphocytes (percent) values reached control non-significant levels in the CME 700 + Cis group ([Table 5](#T5){ref-type="table"}). On the other hand, CME administration in the CME group caused a significant enhancement of the eosinophil values when compared to the control group (*P* \< 0.01).

###### 

White blood cell parameters of the *Cornus mas* fruit hydro-methanolic extract and cisplatin treated rats (n = 8).
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DISCUSSION {#sec1-4}
==========

Using an experimental rat model, we evaluated the lipid profile, hematologic parameters, and the activity of the antioxidant enzymes in cisplatin-treated rats with and without CME co-administration. The cisplatin caused no significant difference to the lipid profile when compared to the control group. The results are consistent with those of Ellis, *et al*., who found no significant adverse effects on the plasma lipid profile after cisplatin chemotherapy in patients([@ref18]). There are, however, some findings that are not in line with our findings. In a study by Abdel- Gayoum, *et al*., on serum total cholesterol, triglyceride concentrations were increased, but no severe changes in LDL- or HDL- cholesterol fractions were observed in nephrotic rats five days after a single cisplatin IP injection([@ref19]). On the other hand, the significant total cholesterol and HDL lowering effects of CME were demonstrated in our findings, which were in agreement with the current understandings of traditional medicine specialists with regard to the cardiovascular protective effects of *C. mas*([@ref8]). There were some reports about the hypolipidemic effects of natural products anthocyanins([@ref20]).

In our study, some results showed an increasing effect of cisplatin on Hb and a decreasing effect of CME on RBCs in rats ([Table 3](#T3){ref-type="table"}). Platelet parameters indicated the enhancement effects of cisplatin on MPV in the Cis group (*P* \< 0.05), and CME on PCT in the CME and CME 300 + Cis groups (*P* \< 0.01). MPV increases during the platelet activation and also during the platelet swelling([@ref21]). Increased MPV indicate a large number of larger and younger platelets in the blood, probably due to the bone marrow rapid production and release into the blood circulation. The MPV values reached non-significant levels in the CME + Cis groups. It is demonstrated that antioxidants reduce the platelet activity through stimulation of prostacyclin synthesis and by scavenging of the peroxides([@ref22][@ref23]). It is evident that polyphenols can stop NADPH oxidase enzyme of platelets. Therefore, inhibiting the production of O~2~^¯^ and increasing the biological power of NO consequently regulates glycoprotein pine receptors on the platelet membrane surface; this, in turn, inhibits the activation of platelets and their adherence during inflammation and thrombosis processes([@ref24]). As a result, it is probable that the antioxidant and phenolic compounds of *C. mas* fruits prevent the platelet activity without bone marrow depression.

In the findings of WBC-related parameters, a significant enhancement in WBC and inflammatory cells (neutrophils, monocytes, basophils, and large unstained cells), as well as a reduction in lymphocytes, was observed in the cisplatin-treated group when compared to the control group. The values of the parameters had a trend to non-significant levels in the co-treated (CME + Cis) groups ([Table 5](#T5){ref-type="table"}). There is evidence to show that the myeloperoxidase (MPO) activity increases in cisplatin-treated rats, indicating that there is high neutrophil infiltration in tissues([@ref25]). The MPO inhibition and interaction activity of the polyphenols, and other antioxidants, were also reported by some researchers([@ref26][@ref27]). Inflammation has an important role in cisplatin-induced pathophysiology and our findings are in accordance with previous studies([@ref28]). Oxidative stress induced by cisplatin can activate the nuclear factor kappa beta (NF-kβ) transcription factor that promotes the production of TNF-α mRNA and TNF-α as the pro-inflammatory cytokines. In cisplatin- induced adverse effects, the levels of the cytokines increase([@ref29]). On the other hand, CME caused a significant increase on eosinophils in the CME-treated group. This may be due to a reduction in the eosinophil apoptosis. Apoptosis of eosinophils is mediated by stimulators of cellular oxidative metabolisms and can be inhibited by antioxidants([@ref30]). The results suggest that the antioxidant properties of CME may inhibit the eosinophil apoptosis.

The findings of the present study showed a significant reduction in GPx and catalase activities and an enhancement in serum MDA values in the cisplatin group, but which were reversed in the control levels in the CME co-treated groups. These results indicate oxidative stress induced by cisplatin, which can protects by CME administration.

The oxidative stress induction by cisplatin has been proven to be involved in cisplatin-induced toxicity([@ref31][@ref32][@ref33]). Oxidative stress, apoptosis, inflammation, and fibrogenesis are involved in the *in vivo* mechanism of cisplatin-induced changes and injuries. Reactive oxygen species (ROS) can directly act on cell components, such as lipids and proteins, and destroy their structure. Cisplatin can increase the presence of the produced ROS through all these pathways, resulting in the pathogenesis of acute cisplatin-induced adverse effects([@ref31]). The increase of the rats\' serum MDA content after cisplatin administration suggests lipid peroxidation, which is in agreement with the results of the previous studies([@ref2][@ref33]). This could be as a result of an increased hydrogen peroxide concentration produced due the depletion of antioxidant enzymes, such as catalase and GPx activities([@ref32]). In the CME analysis, we established that CME has high antioxidant and polyphenol contents ([Table 1](#T1){ref-type="table"}). However, the restoration of GPx and catalase activities and the reduced serum MDA content in the CME co-treated rats suggest an improvement in the *in vivo* antioxidant status, which may be a function of the antioxidant properties of the CME phenolic and antioxidant contents.

CONCLUSION {#sec1-5}
==========

In summary, the results of the present study demonstrate that *C. mas* fruit extract can provide significant protection against unwanted cisplatin-induced changes in serum antioxidant enzymes, lipid profile, and hematologic parameters. There is no evidence to show that natural antioxidants interfere with cancer therapeutics *in vivo*. Moreover, co-administration of natural antioxidants, such as *C. mas*, and chemotherapy drugs, may enhance the effectiveness of the treatment and reduce the unwanted side effects.
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